(Las Vegas, Nevada, USA) Expected launch of potential therapeutic Neoantigen-based Personalized Cancer Therapeutic Vaccines may increase market size in the coming years, assisted by an increase in diagnosed incident population of several cancer indications along with advancements in treatment options, which makes it clear that the upcoming cancer vaccine are majorly expected to boom the overall therapeutic market in the oncology sector by acting as an adjuvant therapy to the already existing Standard of care therapies (SOC).

 

DelveInsight’s ‘Neoantigen-based Personalized Cancer therapeutic Vaccines Competitive Landscape and Market Forecast by 2035’ report delivers an in-depth understanding of the Neoantigen based Personalized Cancer therapeutic Vaccines and the Neoantigen-based personalized cancer therapeutic vaccines emerging market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

 

To know more about the Neoantigen-based Personalized Cancer therapeutic Vaccines report, click here @ Neoantigen-based Personalized Cancer therapeutic Vaccines Market Forecast

 

Some facts of Neoantigen-based Personalized Cancer Therapeutic Vaccines Market are:

• Leading Neoantigen-Based Personalized Cancer Vaccines companies working in the market are BioNTech SE., Gritstone Bio, Inc., Genocea Biosciences, Inc., Moderna, Inc., Agenus, Inc., Immatics N.V., Advaxis, Inc., Precision Biologics, Inc., Gradalis, OSE Immunotherapeutics, Immunitor, Gristone Oncology, Targovax, Hangzhou Neoantigen Therapeutics, Neon Therapeutics and others.
• Vigil, Tedopi (OSE2101), Hepko-V5, GRANITE (GRT-C901) + SLATE (GRT-R902) , GEN-009, TG01 Vaccine, iNeo-Vac-P01, NEO-PV-01 are the emerging drugs that are involved in Neoantigen-based Personalized Cancer therapeutic Vaccines.
• In terms of the cancer indications, the most benefitted one’s with respect to a good number of upcoming vaccines by major key players are Gradalis (Ewing Sarcoma, Ovarian Cancer, melanoma), OSE Immunotherapuetics (NSCLC), and others.
• Neoantigen-based cancer vaccines also target several other indications such as Bone Cancer, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Urothelial Carcinoma, Cutaneous Melanoma, Renal Cell Carcinoma and others, each with their respective sub-types.
• Among the 7MM, NSCLC accounts for 36.7% of market share by 2035 in the United States
• DelveInsight estimates that Brain and Bone cancer will occupy the lowest market share in the overall Neoantigen Cancer Vaccine market.
• Melanoma, and Bladder cancer also accounts for a high market share but not as high as NSCLC in Neoantigen Cancer Vaccine market in the 7MM countries

 

List of Indications Covered:

• Lung Cancer
• Liver Cancer
• Ovarian
• Bladder
• Melanoma
• Colorectal
• Brain
• Renal Cell Carcinoma
• Bone Cancer
• Pancreatic Ductal Adenocarcinoma

 

Request a free sample report of Neoantigen-based Personalized Cancer therapeutic Vaccines market and competitive landscape: https://www.delveinsight.com/sample-request/neoantigen-based-personalized-cancer-therapeutic-vaccines-competitive-landscape

 

Scope of the Neoantigen-based Personalized Cancer therapeutic Vaccines Report:

• This report provide Overview of various construction approaches for Neoantigen-based Personalized Cancer therapeutic Vaccines, including detailed chapters for marketed products and emerging therapies.
• Pipeline analysis across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities.
• Detailed market size of Neoantigen-based Personalized Cancer therapeutic Vaccines, covering the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan by 2035
• Detailed forecasted market covering the United States, EU5, and Japan by 2035

Cancer therapeutic Vaccines use weakened or killed viruses, bacteria, or other germs to start an immune response in the body. These vaccines are designed to work in a similar manner, teaching the immune system to recognize, attack and destroy cancer cells. 

 

Neoantigen-based Personalized Cancer therapeutic Vaccines allows the immune system to recognize cancer cells as foreign, and therefore, get the immune system to attack the cancer cells. Neoantigen-based Personalized Cancer therapeutic Vaccines are one way to utilize the body’s immune system to fight cancer.

 

Request for sample pages @ https://www.delveinsight.com/sample-request/neoantigen-based-personalized-cancer-therapeutic-vaccines-competitive-landscape

 

The pipeline of Neoantigen-based Personalized Cancer therapeutic Vaccines appears to be very promising with availability of vaccines in different stages of development.  The report offers in-depth insights about 10+ Active Players and the Expected launch of 15+ potential Neoantigen-based Personalized Cancer therapeutic Vaccines. There are several key players robustly involved in developing potential products such as Gradalis (Vigil), OSE Immunotherapeutics (Tedopi), Immunitor (Hepko-V5), Gritstone Oncology (GRANITE (GRT-C901) + SLATE (GRT- R902)), Genocea (GEN-009), Targovax (TG01 Vaccine), Hangzhou Neoantigen Therapeutics (iNeo-Vac-P01), Neon Therapeutics (NEO-PV-01) along with many more

 

Neoantigen-based Personalized Cancer therapeutic Vaccines covered in the report are:-

• Vigil
• Tedopi (OSE2101)
• Hepko-V5
• GRANITE (GRT-C901) + SLATE (GRT-R902)
• GEN-009
• TG01 Vaccine
• iNeo-Vac-P01
• NEO-PV-01
• And many others

 

Neoantigen-based Personalized Cancer therapeutic Vaccines Companies covered in the report are:-

• Gradalis
• OSE Immunotherapeutics
• Immunitor
• Gristone Oncology
• Genocea
• Targovax
• Hangzhou Neoantigen Therapeutics
• Neon Therapeutics
• And many others

 

Request for a sample page to know about the Neoantigen-based Personalized Cancer therapeutic Vaccines clinical trials and companies working in the domain @ https://www.delveinsight.com/sample-request/neoantigen-based-personalized-cancer-therapeutic-vaccines-competitive-landscape

 

Table of Contents

1 Key Insights 

2 Neoantigen-based Personalized Cancer therapeutic Vaccines Market Overview at a Glance

3 Neoantigen-based Personalized Cancer therapeutic Vaccines Disease Background and Overview

4 Neoantigen-based Personalized Cancer therapeutic Vaccines Marketed Vaccines

4.1 Tradition/Conventional Cancer Vaccine 

4.2 Provenge (Sipuleucel-T): Dendreon Corporation/Sanpower Group

5 Neoantigen-based Personalized Cancer therapeutic Vaccines Emerging Vaccines 

5.1 Key Cross Competition 

5.2 Key Cross Competition of Phase I Vaccines 

5.3 Vigil: Gradalis

5.4 Tedopi (OSE2101): OSE Immunotherapeutics

5.5 Hepko-V5: Immunitor

5.6 GRANITE (GRT-C901) + SLATE (GRT-R902): Gristone Oncology

5.7 GEN-009: Genocea

5.8 TG01 Vaccine: Targovax

5.9 iNeo-Vac-P01: Hangzhou Neoantigen Therapeutics

5.10 NEO-PV-01: Neon Therapeutics

6 Neoantigen-based Personalized Cancer Vaccines Therapeutic Assessment

7 Comparison of Neoantigen-based Personalized Cancer therapeutic Vaccines by Technology

8 Attribute Analysis of Neoantigen-based Personalized Cancer therapeutic Vaccines

9 Neoantigen-based Personalized Cancer therapeutic Vaccines 7 Major Market Analysis

9.1 Key Findings

9.2 Market Size of Neoantigen-based Personalized Cancer therapeutic Vaccines in the 7MM

9.3 United States Neoantigen-based Personalized Cancer therapeutic Vaccines Market Size

9.4 EU5 Neoantigen-based Personalized Cancer therapeutic Vaccines Market Size

9.5 Germany Neoantigen-based Personalized Cancer therapeutic Vaccines Market Size

9.6 Italy Neoantigen-based Personalized Cancer therapeutic Vaccines Market Size

9.7 Spain Neoantigen-based Personalized Cancer therapeutic Vaccines Market Size

9.8 France Neoantigen-based Personalized Cancer therapeutic Vaccines Market Size

9.9 United Kingdom Neoantigen-based Personalized Cancer therapeutic Vaccines Market Size

9.10 Japan Neoantigen-based Personalized Cancer therapeutic Vaccines market Size

10 Case Reports

11 SWOT Analysis for Neoantigen-based Personalized Cancer therapeutic Vaccines

12 Limitations of cancer treatment vaccines

13 Appendix

14 Neoantigen-based Personalized Cancer therapeutic Vaccines Report Methodology

15 DelveInsight Capabilities

16 Disclaimer

17 About DelveInsight

 

To know more about the Neoantigen-based Personalized Cancer therapeutic Vaccines report, click here @ Neoantigen-based Personalized Cancer therapeutic Vaccines Market Forecast

 

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting